Drugs / ARCT-165
last change Dec 2023 re-read 2 minutes ago

ARCT-165

Developed for
COVID-19
Investigated by
Arcturus Therapeutics, Inc.

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05037097 Aug 2021 → Dec 2023 COVID-19 Arcturus Therapeutics, Inc. Completed No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as ARCT-165 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05037097